| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — |
| Current Ratio | 4.42 | 4.16 | 4.90 | 2.67 | 2.37 | 3.41 | 14.24 | 18.19 | 0.03 |
| Quick Ratio | 4.42 | 4.16 | 4.90 | 2.67 | 2.37 | 3.41 | 14.24 | 18.19 | 0.03 |
| Debt / Equity | — | — | — | — | — | — | — | — | — |
| ROE | -151.18% | -324.41% | -125.46% | -388.57% | -553.72% | -273.28% | -120.32% | -261.89% | 114.23% |
| ROA | -119.54% | -261.65% | -108.16% | -222.08% | -259.84% | -198.36% | -111.87% | -247.51% | -3298.37% |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Book Value / Share | 7.89 | 0.84 | 2.87 | 0.13 | 0.19 | — | — | 18.26 | -5.72 |
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment and prevention of addiction and related disorders. Its lead investigational product, AD04, is a genetically targeted serotonin-3 receptor antagonist designed specifically for Alcohol Use Disorder in patients with certain genotypes, identified through the company's proprietary companion diagnostic genetic test. This precision medicine approach aims to address unmet needs in addiction treatment by tailoring therapy to individual genetic profiles. Adial Pharmaceuticals Inc. is also advancing drug candidates for non-opioid pain reduction and other associated diseases and disorders. The company operates within the health technology sector, contributing to innovative solutions in pharmaceuticals for behavioral health challenges. Founded in 2010 and headquartered in Glen Allen, Virginia, Adial Pharmaceuticals Inc. emphasizes targeted therapies to improve outcomes in addiction management.